COMP <GO>
NEPH vs CVRX // ENTERPRISE SCALE & MARKET CAP
Nephros Inc. (NASDAQ) VS. CVRx Inc. (NASDAQ) • 15-METRIC TALLY: NEPH 6
— CVRX 2
▲ ENTERPRISE SCALE & MARKET CAP LEADER: CVRX
LAST: $3.27 (+3.16%) • MKT CAP: $35.5M
market-cap
$35.5M
LAST: $1.43 (+1.79%) • MKT CAP: $38.0M
market-cap
$38.0M
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NEPH VS. CVRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NEPH | CVRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 61.90% | 85.30% | -23.40 | CVRX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 18.90% | -35.00% | +53.90 | NEPH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 26.3x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 4.50% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | 6.10% | -60.00% | +66.10 | NEPH | /operating-margins <GO> |
| Net Profit Margin | 6.40% | -60.00% | +66.40 | NEPH | /net-margins <GO> |
| Revenue Growth (YoY) | 32.70% | 10.40% | +22.30 | NEPH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 5/9 | +3.00 | NEPH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 36.7 | 31.9 | +4.80 | NEPH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 25.0x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $35.5M | $38.0M | -$2.4M | CVRX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NEPH REV | CVRX REV | NEPH GROSS % | CVRX GROSS % | NEPH FCF | CVRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $18.8M | $56.7M | 61.9% | 85.3% | $1.6M | -$40.8M |
| FY 2024 | $14.2M | $51.3M | 61.6% | 83.8% | -$547.0K | -$40.5M |
| FY 2023 | $14.2M | $39.3M | — | — | $827.0K | -$39.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NEPH // BETA —
CVRX // BETA —